Researchers found that tumors with ALK gene rearrangements can harbor up to 20% of additional mutations, including EGFR and MET genes. These coexisting mutations may impact treatment response to targeted therapies.
Researchers found that intraventricular chemotherapy can palliate associated symptoms in patients with leptomeningeal carcinomatosis from non-small cell lung cancer. The study shows that 20 of 69 patients achieved normal ICP, and careful patient selection is recommended for successful treatment.
A recent study published in the Journal of Thoracic Oncology found that higher primary care provider density is associated with lower lung cancer mortality rates, particularly among white populations. The researchers suggest that interventions aimed at primary care providers may deserve more investigation to improve access to cancer care.
The International Association for the Study of Lung Cancer has developed a guideline for molecular testing in lung cancer, recommending testing for EGFR and ALK abnormalities in all patients with advanced lung adenocarcinoma. This approach provides individualized treatment options and improved quality of life for patients.
A survey by the IASLC found that 90% of physicians believe tobacco cessation is essential for lung cancer treatment, but only 39% provide assistance. The study highlights barriers to effective tobacco cessation support for cancer patients.
A study published by the International Association for the Study of Lung Cancer found that 54% of patients with early stage node-negative lung adenocarcinoma had tumors with at least one biologically relevant mutation. The researchers also discovered mutations associated with drug resistance in these patients.
Researchers found local therapy combined with continued EGFR TKI therapy to be well-tolerated and effective in prolonging progression-free and overall survival. Local therapy was associated with a median overall survival of 41 months, a median time to progression of 10 months.
A study found that elderly patients are significantly underrepresented in clinical trials, with only 33% of highly cited trials excluding them. Researchers recommend increasing age diversity to better represent the median age of advanced NSCLC patients.
Researchers found cancers with EGFR exon 20 insertions have similar clinical characteristics to those with common mutations but a poorer prognosis. Median survival was 16 months for these patients, shorter than those with other mutations.
Researchers compared the patterns of failure between stereotactic body radiotherapy (SBRT), lobectomy, and pneumonectomy for patients with stage I non-small-cell lung cancer. The results show comparable patterns of failure, but highlight the challenges in making such comparisons due to differences in patient and tumor-related factors.
A recent study by IASLC found that EGFR mutations do not serve as a prognostic factor in NSCLC patients. Instead, smoking status appears to be the most significant predictor of overall survival. The researchers also discovered that administering EGFR TKI can prolong survival after disease recurrence.
A recent study found immunohistochemistry to be a reliable and accurate method for detecting ALK rearrangement in non-small cell lung cancer. The technique outperformed fluorescence in situ hybridization, which is currently the standard but time-consuming method.
A new study validates the IASLC/ATS/ERS classification for lung adenocarcinomas among Japanese patients, revealing prognostic value in histologic subtypes. The classification identifies specific molecular markers, such as EGFR and KRAS mutations, associated with prognosis and treatment outcomes.
A recent study published in the Journal of Thoracic Oncology found that COPD is not an independent risk factor for lung cancer. Researchers associated COPD with lung cancer, but attributed this link to smoking and ascertainment bias, highlighting the need for lung cancer screenings when diagnosing COPD.
A study published in the Journal of Thoracic Oncology found that denosumab was associated with significantly improved overall median survival in lung cancer patients, including those with non-small-cell lung cancer and small-cell lung cancer. The treatment also showed improved survival in patients with squamous cell carcinoma.
Researchers have successfully genotyped 344 NSCLC specimens with a median turnaround time of 31 days, enabling targeted therapy. This study's findings highlight the potential for large-scale genomic testing to transform lung cancer treatment.
Researchers found that local ablative therapy and continuation of targeted drugs can prolong disease control by up to 6.2 months in patients with EGFR mutations or ALK rearrangements. The study's findings suggest a new approach to treating NSCLC after progression, particularly for patients with oligoprogressive disease.
A study published in the Journal of Thoracic Oncology found that fit elderly patients with non-small cell lung cancer can benefit from salvage targeted therapy without increased toxicity. The study analyzed data from 255 patients and showed no difference in response rates or progression-free survival between age groups.
A study analyzing the International Mesothelioma Interest Group (IMIG) staging system for malignant pleural mesothelioma (MPM) reveals areas for potential revision. The current system distinguishes among T and N categories, but qualitative T descriptors may not be applicable to clinical staging.
A study published in the Journal of Thoracic Oncology found that VeriStrat can predict response to erlotinib, but does not provide a survival benefit. The test showed a significant difference in median survival between good and poor responders, with good responders experiencing longer survival on erlotinib.
A pilot study found that breath testing can accurately discriminate between benign and malignant pulmonary nodules. The technique, using volatile organic compounds and chemical nanoarrays, identified 53 malignant and 19 benign nodules with high accuracy.
Researchers from the British Columbia Cancer Research Center analyzed lung tumors exposed to arsenic, highlighting genetic and epigenetic changes driving carcinogenesis. These findings may help prevent arsenic-related cancer in regions with low exposure levels.
Researchers are developing a multiple marker test in peripheral blood to detect lung cancer, promising an earlier diagnosis. The test discriminated between healthy donors and patients with non-small cell lung cancer (NSCLC) with high accuracy.
Scientists investigate the use of novel AKT inhibitor MK-2206 in combination with erlotinib as a second-line defense for patients with non-small cell lung cancer (NSCLC) who have developed resistance to erlotinib. A Phase II trial has shown promising initial results.
Researchers at Kaiser Permanente Southern California identified 7,112 patients with lung nodules using existing medical records. They developed an automated method that classifies nodules with 96% sensitivity and 86% specificity compared to clinician review.
A study published in the Journal of Thoracic Oncology found that stereotactic ablative radiotherapy is an effective treatment option for elderly patients with stage I non-small cell lung cancer. The treatment did not negatively impact health-related quality of life, and functional and symptom outcomes remained stable after two years.
A study published by the International Association for the Study of Lung Cancer found that high-volume hospitals and thoracic surgeons have lower mortality rates compared to general surgeons. The researchers recommend a national audit program to evaluate institutions based on quality parameters, including hospital volume.
Researchers found that perioperative chemotherapy improved overall survival in patients with limited large cell neuroendocrine tumors or small-cell lung cancer after surgery. The study of 74 patients showed a significant difference in overall survival between those who received chemotherapy and those who did not.
A recent study found VATS resection in CT-screened high-risk Danish population yielded higher incidence of early stage lung cancer. The study detected 68 lung cancers in the screened group versus 24 in the unscreened group, with 51 patients suitable for surgery and 84% undergoing VATS.
A recent study suggests a positive correlation between tumor size and chemotherapy efficacy in surgically resected patients with node-negative non-small cell lung cancer. The study found no clear threshold for tumor size that correlated with a benefit from chemotherapy.
Researchers found that tenasin-C gene expression and nodule size can predict lung cancer with improved accuracy. The study used bronchoscopic microsampling to collect fluid from lung nodules, showing promise for a less invasive diagnostic technique.
Researchers found that fine needle aspiration is highly sensitive for diagnosing lung cancer, but has a high rate of false negatives, especially in larger lesions. The study recommends repeat imaging to monitor for growth and suggests this method can help patients avoid unnecessary surgery.
A recent study published in the Journal of Thoracic Oncology reveals that Japanese patients with lung cancer are more likely to harbor specific genetic mutations and have a different risk profile compared to Western patients. The research highlights the importance of considering genetic factors in lung cancer diagnosis and treatment.
Researchers analyzed four studies and found that regular follow-up reduces crisis-driven health episodes. While no preferred method was determined, the authors recommend guidelines for initial specialist appointments and protocol-driven follow-up led by a lung cancer clinical nurse specialist.
A recent study published in Journal of Thoracic Oncology suggests that CYFRA21-1 levels can reliably indicate patient response to chemotherapy for non-small cell lung cancer (NSCLC). Higher baseline concentrations were linked to poorer overall and failure-free survival. Further research is needed to confirm these findings.
A recent study published in the Journal of Thoracic Oncology suggests that pleurectomy/decortication (P/D) is a superior approach to extrapleural pnemonectomy (EPP) for patients with early-stage malignant pleural mesothelioma. P/D resulted in significantly better survival rates and lower mortality and morbidity compared to EPP.
A panel of 10 serum protein biomarkers shows promise in predicting lung cancer risk and aiding early detection. Research suggests that these biomarkers could reduce the number of unnecessary lung biopsies needed, offering a more targeted approach to diagnosis.
Lung cancer patients face geographic challenges to access clinical trials due to molecular preselection. Researchers propose using online patient communities and innovative trial approaches to inform patients about trials, accelerate research, and address practical challenges in conducting personalized medicine trials.
Research finds a significant association between pulmonary TB and EGFR mutations in lung cancer patients. The study reveals that tumors with these mutations respond well to targeted therapies, offering new hope for treatment.
The IASLC has set up a Strategic CT Screening Advisory Committee to define optimal approaches to lung cancer screening. The committee will focus on six key components, including identifying high-risk individuals and developing radiological guidelines for national screening programs.
Researchers found that lung cancer patients with diabetes had higher survival rates, including 43% at 1-year and 28% without diabetes. The benefits were seen across different stages of disease, suggesting that diabetes may not be a reason to withhold standard treatment.
A study found that ALK-rearranged non-small cell lung cancer patients responded significantly better to pemetrexed than those without the genetic mutation. Researchers discovered that ALK positivity was an independent predictor for pemetrexed efficacy, with improved tumor response rates and longer time to progression.
Researchers found that fibrous stroma surrounding squamous cell carcinoma tumors was associated with reduced 5-year recurrence-free survival and overall survival rates. The study suggests that targeting the tumor microenvironment may be a meaningful approach for developing treatment strategies.
A new, cost-effective method for detecting ALK rearrangement in non-small cell lung cancer patients has been developed. This approach is comparable to the established gold standard, fluorescence in situ hybridization (FISH), and could enable more patients to access potentially life-saving crizotinib therapy.
A new study published in the Journal of Thoracic Oncology found that endosonography followed by surgical staging significantly improved the quality of life for lung cancer patients. The study, which compared two strategies for mediastinal staging, showed no significant difference in costs between the two approaches.
The TEMLA procedure demonstrated a higher diagnostic yield than EBUS and EUS in detecting cancer in primary staging, with a sensitivity of 98.6% compared to 88.9% for EBUS/EUS. Additionally, TEMLA showed superior performance in restaging procedures, with a sensitivity of 95.5% and specificity of 100%.
Research suggests that adding an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux does not improve treatment outcomes for cancer patients with blood clots. In fact, median survival was shorter and VTE resolution rates were lower in patients who received both treatments.
A Phase III trial found that amrubicin significantly improved tumor shrinkage, symptom control, and progression-free survival compared to topotecan in lung cancer patients. Patients treated with amrubicin also reported better quality of life and fewer adverse events.
New treatment options, including stereotactic ablative radiotherapy, have led to significant improvements in the survival of elderly Dutch lung cancer patients. Median survival for NSCLC patients increased by nearly 8 months between 2003 and 2009.
The Cancer Risk Management model uses dynamic simulations to project realistic Canadian populations, offering insights into screening, prevention, and treatment changes. By reducing smoking rates, the model predicts a decrease in lung cancer incidence and cumulative savings in direct treatment costs.